Qube Research & Technologies LTD T Scan Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $61.9 Billion
- Q1 2024
A detailed history of Qube Research & Technologies LTD transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 143,536 shares of TCRX stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
143,536
Previous 79,989
79.44%
Holding current value
$1.23 Million
Previous $466,000
144.42%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TCRX
# of Institutions
67Shares Held
29.3MCall Options Held
0Put Options Held
0-
Eco R1 Capital, LLC San Francisco, CA5MShares$42.8 Million1.13% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.9MShares$33.3 Million0.06% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$25.6 Million0.71% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$23.8 Million0.28% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$17.8 Million9.65% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $162M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...